Navigation Links
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
Date:5/14/2012

CRANBURY, N.J., May 14, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its third quarter ended March 31, 2012.  Palatin reported a net loss of $6.0 million, or $(0.17) per basic and diluted share, for the quarter ended March 31, 2012, compared to a net loss of $3.8 million, or $(0.17) per basic and diluted share, for the same period in 2011. 

The increase in net loss for the quarter ended March 31, 2012, compared to the same period last fiscal year, is mainly attributable to costs related to Palatin's ongoing Phase 2B clinical trial with bremelanotide for Female Sexual Dysfunction (FSD), which commenced in June 2011.

REVENUE
Revenues for the quarter ended March 31, 2012 were $23,996, compared to $61,294 for the quarter ended March 31, 2011.  Revenue consists of contract revenue under its collaboration agreement with AstraZeneca.

COSTS AND EXPENSES
Total operating expenses for the quarter ended March 31, 2012 were $6.1 million compared to $2.7 million for the comparable quarter of 2011.  The increase in operating expenses for the quarter was primarily due to costs related to Palatin's ongoing Phase 2B clinical trial with bremelanotide for FSD.

CASH POSITION
Palatin's cash and cash equivalents as of March 31, 2012 were $8.8 million and current liabilities were $3.4 million.  Cash and cash equivalents as of June 30, 2011 were $18.9 million with current liabilities of $2.8 million. 

Palatin believes, based on its current operating plan, that its cash and cash equivalents at March 31, 2012, will be sufficient to fund its operations through March 31, 2013.

'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Mechanicsburg, Pa (PRWEB) May 20, 2013 ... controller with ramp/soak capabilities. The 5R6-900 benchtop controller ... enclosure, the device can be plugged into the wall ... own power supply. This distinctive detail makes the device ... , The laboratory temperature controller can also be ...
(Date:5/20/2013)... Today, at the American Psychiatric Association (APA) ... James McGough , M.D., M.S., principal investigator ... for Neuroscience and Human Behavior and David ... of California Los Angeles (UCLA), and director of clinical ... ADHD at UCLA, presented the results of a Phase ...
(Date:5/20/2013)... DIEGO , May 20, 2013  Dr. ... field of nucleic acid research, recently launched a new ... In with Zon ( zon.trilinkbiotech.com ), focuses on what,s ... include interviews with industry thought leaders, discussions of research ... and more. Dr. Zon (PhD Princeton ...
(Date:5/20/2013)... 20, 2013 With bed bugs' presence come ... although bed bugs need to be eliminated, one must make ... a person's health. And so to help bed bug sufferers ... get rid of bed bugs without using harmful pesticides. ... spray it called Bed Bug Bully. , According to My ...
Breaking Biology Technology:New Laboratory Temperature Controller by Oven Industries 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2New Non Pesticide Discovery on How to Get Rid of Bed Bugs Tipped by My Cleaning Products 2
... BIRMINGHAM, Ala., Sept. 19 BioCryst,Pharmaceuticals, Inc. ... findings,from a Phase II study with intramuscular ... for the treatment of seasonal and,life-threatening influenza. ... The study was a randomized, double-blind, placebo-controlled ...
... ,Arpida Ltd (SWX: ARPN) presented a large body ... iclaprim at the 47th annual Interscience,Conference on Antimicrobial ... major scientific conference where thousands of scientists and,clinicians ... the latest,developments in the field of infectious diseases. ...
... bacterial contamination in ... platelets, WORCESTER, ... for detecting bacterial contaminants in,blood cells and tissue, has received 510 (k) ... Administration (FDA). This provides,Verax authorization to market the device, which cuts the ...
Cached Biology Technology:BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 3BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 4BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 5BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 6BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 7Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 2Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 3Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 4Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test 2Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test 3
(Date:5/20/2013)... of Minnesota Medical School researchers from the Masonic Cancer ... Brain Tumor Program, have developed a new mouse model ... them to discover new genes and gene pathways driving ... this week in the journal Nature Genetics . ... the lab of David Largaespada, Ph.D., professor in the ...
(Date:5/20/2013)... 20, 2013) - A novel vaccine study ... groundbreaking research that will be unveiled at the American ... The meeting takes place Monday, May 20 - Wednesday, ... Marina. , "The main goal of a vaccine ... a pathogen that causes the disease", explained Dr. Hemachand ...
(Date:5/19/2013)... Scientists at the University of California, Davis have engineered ... need for light. They report their findings today ... for Microbiology. , "In this work, we used synthetic ... on carbon dioxide and light energy for growth) cyanobacterial ... says Jordan McEwen, the lead researcher on the study. ...
Breaking Biology News(10 mins):U of M researchers develop model for better testing, targeting of MPNST 2Germ-fighting vaccine system makes great strides in delivery 2
... University have developed a technique that uses a ... particles within seconds, representing a potential new tool ... nanoassembly. The technique, called rapid electrokinetic patterning, ... the patterns can be more quickly and easily ...
... Conn.Organizations in the United States that are at the ... not adapting enough to the dangers posed by rising ... half century of climate change that has already significantly ... widespread ecological and hydrological impacts, and despite a near ...
... (DFG, German Research Foundation) will launch ten new Collaborative ... next four years with a total of approximately 90 ... Centres will study the origins of diseases caused by ... and the human skin. Other topics include the optimisation ...
Cached Biology News:New holographic method could be used for lab-on-a-chip technologies 2New holographic method could be used for lab-on-a-chip technologies 3New holographic method could be used for lab-on-a-chip technologies 4Most US organizations not adapting to climate change 2Most US organizations not adapting to climate change 3From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 2From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 3From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 4From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 5From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 6From sheet metal elements to host cells: DFG launches 10 new collaborative research centers 7
...
...
... The greater incorporation of Br-dUTP results in ... detected using a fluorescein-labeled anti-BrdU antibody. ... the kit to counterstain the total DNA. ... resulting in improved detection than found by ...
Mouse monoclonal antibody raised against a partial recombinant FBXO24. NCBI Entrez Gene ID = FBXO24...
Biology Products: